Jodie Ingles

List of Publications by Citations

146 papers	4,745 citations	35 h-index	66 g-index
182 ext. papers	6,504 ext. citations	5.5 avg, IF	5.78 L-index

#	Paper	IF	Citations
146	New perspectives on the prevalence of hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2015**, 65, 1249-1254	15.1	557
145	A Prospective Study of Sudden Cardiac Death among Children and Young Adults. *New England Journal of Medicine*, **2016**, 374, 2441-52	59.2	396
144	Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. *Journal of Medical Genetics*, **2005**, 42, e59	5.8	270
143	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*, **2019**, 16, e301-e372	6.7	247
142	Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel. *Genetics in Medicine*, **2018**, 20, 351-359	8.1	173
141	Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. *European Heart Journal*, **2015**, 36, 1290-6	9.5	144
140	Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. *Journal of the American College of Cardiology*, **2010**, 55, 1127-35	15.1	137
139	Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002460	5.2	132
138	Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. *Journal of the American College of Cardiology*, **2018**, 72, 419-429	15.1	92
137	A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. *Heart*, **2012**, 98, 625-30	5.1	83
136	The emerging role of the cardiac genetic counselor. *Heart Rhythm*, **2011**, 8, 1958-62	6.7	82
135	Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. *Genetics in Medicine*, **2013**, 15, 972-7	8.1	79
134	Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy. *Genetics in Medicine*, **2008**, 10, 117-20	8.1	79
133	Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. *Circulation: Cardiovascular Genetics*, **2017**, 10,		75
132	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. *Heart Rhythm*, **2019**, 16, e373-e407	6.7	73
131	Sudden cardiac death in the young: a clinical genetic approach. *Internal Medicine Journal*, **2007**, 37, 32-7	1.6	66
130	Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults with genetic heart disease. *International Journal of Cardiology*, **2013**, 168, 3779-84	3.2	65

129	Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2004**, 93, 1192-4	3	63
128	Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2007**, 43, 337-43	5.8	61
127	Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. *Genetics in Medicine*, **2014**, 16, 286-93	8.1	60
126	Guidelines for genetic testing of inherited cardiac disorders. *Heart Lung and Circulation*, **2011**, 20, 681-7	1.8	56
125	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. *European Heart Journal*, **2019**, 40, 2953-2961	9.5	53
124	Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. *Circulation: Heart Failure*, **2019**, 12, e005371	7.6	51
123	A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. *Circulation*, **2020**, 142, 217-229	16.7	51
122	Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2011**, 152, 258-9	3.2	51
121	Multiple Gene Variants in Hypertrophic Cardiomyopathy in the Era of Next-Generation Sequencing. *Circulation: Cardiovascular Genetics*, **2017**, 10,		45
120	Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. *JAMA Cardiology*, **2017**, 2, 1153-1160	16.2	45
119	A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*, **2016**, 13, 1652-60	6.7	43
118	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. *Circulation*, **2020**, 141, 1371-1383	16.7	43
117	Conveying a probabilistic genetic test result to families with an inherited heart disease. *Heart Rhythm*, **2014**, 11, 1073-8	6.7	41
116	Sex hormone receptor gene variation associated with phenotype in male hypertrophic cardiomyopathy patients. *Journal of Molecular and Cellular Cardiology*, **2008**, 45, 217-22	5.8	39
115	Interdisciplinary psychosocial care for families with inherited cardiovascular diseases. *Trends in Cardiovascular Medicine*, **2016**, 26, 647-53	6.9	38
114	Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences. *Journal of Molecular and Cellular Cardiology*, **2005**, 38, 387-93	5.8	37
113	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. *Heart Rhythm*, **2021**, 18, e1-e50	6.7	37
112	Genome sequencing as a first-line genetic test in familial dilated cardiomyopathy. *Genetics in Medicine*, **2019**, 21, 650-662	8.1	36

111	Health status of cardiac genetic disease patients and their at-risk relatives. *International Journal of Cardiology*, **2013**, 165, 448-53	3.2	35
110	Application of Genetic Testing in Hypertrophic Cardiomyopathy for Preclinical Disease Detection. *Circulation: Cardiovascular Genetics*, **2015**, 8, 852-9		35
109	Postmortem molecular analysis of KCNQ1 and SCN5A genes in sudden unexplained death in young Australians. *International Journal of Cardiology*, **2008**, 127, 138-41	3.2	35
108	Prolongation of the QTc interval predicts appropriate implantable cardioverter-defibrillator therapies in hypertrophic cardiomyopathy. *JACC: Heart Failure*, **2013**, 1, 149-55	7.9	34
107	Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. *American Journal of Cardiology*, **2005**, 95, 991-3	3	34
106	Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. *Circulation*, **2021**, 144, 7-19	16.7	34
105	Posttraumatic Stress and Prolonged Grief After the Sudden Cardiac Death of a Young Relative. *JAMA Internal Medicine*, **2016**, 176, 402-5	11.5	33
104	Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2004**, 96, 157-63	3.2	33
103	Factors influencing uptake of familial long QT syndrome genetic testing. *American Journal of Medical Genetics, Part A*, **2016**, 170A, 418-425	2.5	31
102	The value of cardiac genetic testing. *Trends in Cardiovascular Medicine*, **2014**, 24, 217-24	6.9	29
101	Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers. *Open Heart*, **2016**, 3, e000484	3	26
100	Molecular autopsy in victims of inherited arrhythmias. *Journal of Arrhythmia*, **2016**, 32, 359-365	1.5	26
99	Tweeting our way to cardiovascular health. *Journal of the American College of Cardiology*, **2013**, 61, 1657-8	15.1	24
98	Cardiovascular Effects of Energy Drinks in Familial Long QT Syndrome: A Randomized Cross-Over Study. *International Journal of Cardiology*, **2017**, 231, 150-154	3.2	23
97	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. *JAMA Cardiology*, **2020**, 5, 83-91	16.2	23
96	Poor psychological wellbeing particularly in mothers following sudden cardiac death in the young. *European Journal of Cardiovascular Nursing*, **2013**, 12, 484-91	3.3	22
95	Communication of genetic information to families with inherited rhythm disorders. *Heart Rhythm*, **2018**, 15, 780-786	6.7	21
94	Concealed Arrhythmogenic Right Ventricular Cardiomyopathy in Sudden Unexplained Cardiac Death Events. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002355	5.2	21

93	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 1988-1996	9.5	20
92	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. *Heart Lung and Circulation*, **2021**, 30, 324-349	1.8	20
91	Attitudes, knowledge and consequences of uncertain genetic findings in hypertrophic cardiomyopathy. *European Journal of Human Genetics*, **2017**, 25, 809-815	5.3	19
90	Genetic testing for inherited heart diseases: longitudinal impact on health-related quality of life. *Genetics in Medicine*, **2012**, 14, 749-752	8.1	19
89	Spatial and Functional Distribution of Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2020**, 13, 396-405	5.2	19
88	Exome sequencing-based molecular autopsy of formalin-fixed paraffin-embedded tissue after sudden death. *Genetics in Medicine*, **2017**, 19, 1127-1133	8.1	18
87	Delay to diagnosis amongst patients with catecholaminergic polymorphic ventricular tachycardia. *International Journal of Cardiology*, **2014**, 176, 1402-4	3.2	18
86	Key Value of RNA Analysis of MYBPC3 Splice-Site Variants in Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002368	5.2	18
85	Perceptions of genetic variant reclassification in patients with inherited cardiac disease. *European Journal of Human Genetics*, **2019**, 27, 1134-1142	5.3	17
84	The Australian Genetic Heart Disease Registry. *International Journal of Cardiology*, **2013**, 168, e127-8	3.2	17
83	Relations between right ventricular morphology and clinical, electrical and genetic parameters in Brugada Syndrome. *PLoS ONE*, **2018**, 13, e0195594	3.7	16
82	Temporal Trends in Sudden Cardiac Death From 1997 to 2010: A Data Linkage Study. *Heart Lung and Circulation*, **2017**, 26, 808-816	1.8	15
81	Social determinants of health in the setting of hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2015**, 184, 743-749	3.2	14
80	Psychosocial Implications of Living with Catecholaminergic Polymorphic Ventricular Tachycardia in Adulthood. *Journal of Genetic Counseling*, **2018**, 27, 549-557	2.5	14
79	Minding the Genes: a Multidisciplinary Approach towards Genetic Assessment of Cardiovascular Disease. *Journal of Genetic Counseling*, **2017**, 26, 224-231	2.5	14
78	Challenges of exercise recommendations and sports participation in genetic heart disease patients. *Circulation: Cardiovascular Genetics*, **2015**, 8, 178-86		14
77	Genetic Testing in Inherited Heart Diseases. *Heart Lung and Circulation*, **2020**, 29, 505-511	1.8	14
76	Molecular diagnostics of cardiomyopathies: the future is here. *Circulation: Cardiovascular Genetics*, **2011**, 4, 103-4		13

75	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of -Catecholaminergic Polymorphic Ventricular Tachycardia. *Circulation*, **2020**, 142, 932-947	16.7	12
74	Burden of Recurrent and Ancestral Mutations in Families With Hypertrophic Cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2017**, 10,		11
73	Psychological adaptation to molecular autopsy findings following sudden cardiac death in the young. *Genetics in Medicine*, **2019**, 21, 1452-1456	8.1	11
72	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003062	5.2	10
71	Psychosocial Impact of a Positive Gene Result for Asymptomatic Relatives at Risk of Hypertrophic Cardiomyopathy. *Journal of Genetic Counseling*, **2018**, 27, 1040-1048	2.5	10
70	Establishment of an Australian National Genetic Heart Disease Registry. *Heart Lung and Circulation*, **2008**, 17, 463-7	1.8	10
69	Genetic architecture of left ventricular noncompaction in adults. *Human Genome Variation*, **2020**, 7, 33	1.8	10
68	Implantable cardioverter-defibrillator therapy in Australia, 2002-2015. *Medical Journal of Australia*, **2018**, 209, 123-129	4	10
67	Lack of genotype-phenotype correlation in Brugada Syndrome and Sudden Arrhythmic Death Syndrome families with reported pathogenic SCN1B variants. *Heart Rhythm*, **2018**, 15, 1051-1057	6.7	10
66	Homozygous mutation in the cardiac troponin I gene: clinical heterogeneity in hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2013**, 168, 1530-1	3.2	9
65	Psychosocial care and cardiac genetic counseling following sudden cardiac death in the young. *Progress in Pediatric Cardiology*, **2017**, 45, 31-36	0.4	8
64	Genetic Testing for Cardiomyopathies in Clinical Practice. *Heart Failure Clinics*, **2018**, 14, 129-137	3.3	8
63	A Control Theory-Based Pilot Intervention toIncrease Physical Activity in Patients WithHypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2018**, 122, 866-871	3	8
62	A balanced translocation disrupting SCN5A in a family with Brugada syndrome and sudden cardiac death. *Heart Rhythm*, **2019**, 16, 231-238	6.7	8
61	Exome sequencing identifies a novel mutation in the gene in a family with early-onset sinus node dysfunction, ventricular arrhythmias, and cardiac arrest. *HeartRhythm Case Reports*, **2015**, 1, 141-145	1	7
60	Psychological Issues in Managing Families with Inherited Cardiovascular Diseases. *Cold Spring Harbor Perspectives in Medicine*, **2020**, 10,	5.4	7
59	Rare desmin variant causing penetrant life-threatening arrhythmic cardiomyopathy. *HeartRhythm Case Reports*, **2018**, 4, 318-323	1	7
58	Clinical and genetic features of Australian families with long QT syndrome: A registry-based study. *Journal of Arrhythmia*, **2016**, 32, 456-461	1.5	7

57	Rarity and phenotypic heterogeneity provide challenges in the diagnosis of Andersen-Tawil syndrome: Two cases presenting with ECGs mimicking catecholaminergic polymorphic ventricular tachycardia (CPVT). *International Journal of Cardiology*, **2015**, 201, 473-5	3.2	6
56	Development of a communication aid for explaining hypertrophic cardiomyopathy genetic test results. *Pilot and Feasibility Studies*, **2017**, 3, 53	1.9	6
55	Needs analysis of parents following sudden cardiac death in the young. *Open Heart*, **2020**, 7,	3	6
54	"Concealed cardiomyopathy" as a cause of previously unexplained sudden cardiac arrest. *International Journal of Cardiology*, **2021**, 324, 96-101	3.2	6
53	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 3932-3944	9.5	6
52	Revisiting Genome Sequencing Data in Light of Novel Disease Gene Associations. *Journal of the American College of Cardiology*, **2019**, 73, 1365-1366	15.1	5
51	Impact of the implantable cardioverter defibrillator on confidence to undertake physical activity in inherited heart disease: A cross-sectional study. *European Journal of Cardiovascular Nursing*, **2017**, 16, 742-752	3.3	5
50	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2021**,	3.9	5
49	Transcriptome Sequencing of Patients With Hypertrophic Cardiomyopathy Reveals Novel Splice-Altering Variants in. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003202	5.2	5
48	Discordant clinical features of identical hypertrophic cardiomyopathy twins. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	5
47	Epidemiology and clinical characteristics of atrial fibrillation in patients with inherited heart diseases. *Journal of Cardiovascular Electrophysiology*, **2020**, 31, 465-473	2.7	4
46	Sudden cardiac death rates in an Australian population: a data linkage study. *Australian Health Review*, **2015**, 39, 561-567	1.8	4
45	Sudden deaths during the largest community running event in Australia: A 25-year review. *International Journal of Cardiology*, **2016**, 203, 1029-31	3.2	4
44	Characterization of clinically relevant copy-number variants from exomes of patients with inherited heart disease and unexplained sudden cardiac death. *Genetics in Medicine*, **2021**, 23, 86-93	8.1	4
43	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. *Genetics in Medicine*, **2021**, 23, 69-79	8.1	4
42	Hypertrophic Cardiomyopathy: Genetic Testing and Risk Stratification. *Current Cardiology Reports*, **2021**, 23, 9	4.2	4
41	NOS1AP Polymorphisms Modify QTc Interval Duration But Not Cardiac Arrest Risk in Hypertrophic Cardiomyopathy. *Journal of Cardiovascular Electrophysiology*, **2015**, 26, 1346-51	2.7	3
40	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. *Genetics in Medicine*, **2021**, 23, 1281-1287	8.1	3

39	Genetic variants associated with inherited cardiovascular disorders among 13,131 asymptomatic older adults of European descent. *Npj Genomic Medicine*, **2021**, 6, 51	6.2	3
38	2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. *Journal of Arrhythmia*, **2021**, 37, 481-534	1.5	3
37	LAMP2 shines a light on cardiomyopathy in an athlete. *HeartRhythm Case Reports*, **2017**, 3, 172-176	1	2
36	Response by Ingles and Semsarian to Letter Regarding Article, "Concealed Arrhythmogenic Right Ventricular Cardiomyopathy in Sudden Unexplained Cardiac Death Events". *Circulation Genomic and Precision Medicine*, **2019**, 12, e002475	5.2	2
35	Daily Step Count as a Simple Marker of Disease Severity in Hypertrophic Cardiomyopathy. *Heart Lung and Circulation*, **2018**, 27, 752-755	1.8	2
34	Reply: What Is the True Prevalence of Hypertrophic Cardiomyopathy?. *Journal of the American College of Cardiology*, **2015**, 66, 1846-1847	15.1	2
33	Routinely collected health data to study inherited heart disease: a systematic review (2000-2016). *Open Heart*, **2017**, 4, e000686	3	2
32	Patients With Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement. *Heart Lung and Circulation*, **2020**, 29, e85-e87	1.8	2
31	Prevalence of Anderson-Fabry disease in a cohort with unexplained late gadolinium enhancement on cardiac MRI. *International Journal of Cardiology*, **2020**, 304, 122-124	3.2	2
30	How Patient Perceptions Shape Responses and Outcomes in Inherited Cardiac Conditions. *Heart Lung and Circulation*, **2020**, 29, 641-652	1.8	2
29	Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients With Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2021**, 14, e007537	7.6	2
28	Precision Medicine in Cardiovascular Disease: Genetics and Impact on Phenotypes: JACC Focus Seminar 1/5. *Journal of the American College of Cardiology*, **2021**, 77, 2517-2530	15.1	2
27	The genetic architecture of Plakophilin 2 cardiomyopathy. *Genetics in Medicine*, **2021**, 23, 1961-1968	8.1	2
26	The End Unexplained Cardiac Death (EndUCD) Registry for Young Australian Sudden Cardiac Arrest. *Heart Lung and Circulation*, **2021**, 30, 714-720	1.8	2
25	Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment. *Current Heart Failure Reports*, **2021**, 18, 264-273	2.8	2
24	Global approaches to cardiogenetic evaluation after sudden cardiac death in the young: A survey among health care professionals. *Heart Rhythm*, **2021**, 18, 1637-1644	6.7	2
23	A clinical approach to genetic testing for non-specialists. *BMJ, The*, **2017**, 358, j4101	5.9	1
22	Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. *American Heart Journal*, **2019**, 214, 28-35	4.9	1

21	Evaluating a custom-designed aid to improve communication of genetic results in families with hypertrophic cardiomyopathy: study protocol for a randomised controlled trial. *BMJ Open*, **2019**, 9, e026627	3	1
20	Letter by Semsarian and Ingles regarding article, "A randomized trial of social media from Circulation". *Circulation*, **2015**, 131, e394	16.7	1
19	Genetics of HCM and Role of Genetic Testing **2015**, 77-84		1
18	What do we do and how do we do it? Assessing genetic counselling in the modern era. *European Journal of Human Genetics*, **2020**, 28, 1137-1138	5.3	1
17	Mutation analysis of the natriuretic peptide precursor B (NPPB) gene in patients with hypertrophic cardiomyopathy. *DNA Sequence*, **2006**, 17, 392-5		1
16	Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations. *PLoS ONE*, **2020**, 15, e0236814	3.7	1
15	Investigation of current models of care for genetic heart disease in Australia: A national clinical audit. *International Journal of Cardiology*, **2021**, 330, 128-134	3.2	1
14	Harmonizing the Collection of Clinical Data on Genetic Testing Requisition Forms to Enhance Variant Interpretation in Hypertrophic Cardiomyopathy (HCM): A Study from the ClinGen Cardiomyopathy Variant Curation Expert Panel. *Journal of Molecular Diagnostics*, **2021**, 23, 589-598	5.1	1
13	Sex Disparities in Sudden Cardiac Death. *Circulation: Arrhythmia and Electrophysiology*, **2021**, 14, e009834	6.4	1
12	A prospective longitudinal study of health-related quality of life and psychological wellbeing after an implantable cardioverter-defibrillator in patients with genetic heart diseases.. *Heart Rhythm O2*, **2022**, 3, 143-151	1.5	0
11	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. *Internal Medicine Journal*, **2021**, 51, 769-779	1.6	0
10	Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. *American Journal of Preventive Cardiology*, **2021**, 6, 100151	1.9	0
9	Genetics of HCM and Role of Genetic Testing **2019**, 83-91		0
8	Arrhythmia in Cardiomyopathy: Sex and Gender Differences. *Current Heart Failure Reports*, **2021**, 18, 274-283	2.8	0
7	Whole genome sequencing delineates regulatory, copy number, and cryptic splice variants in early onset cardiomyopathy.. *Npj Genomic Medicine*, **2022**, 7, 18	6.2	0
6	Genetic Testing **2018**, 668-673		
5	Clinical Genetics **2020**, 27-50		
4	Clinical Genetics **2016**, 25-47		

3 Genetic Testing **2014**, 685-690

2 Response to Brodehl et al. *Genetics in Medicine*, **2019**, 21, 1248-1249 8.1

1 Inherited cardiomyopathies **2021**, 277-290